Skip to main content
Signal8
Launch Terminal

Immunome Inc. (IMNM)

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Immunome, Inc. logo

Immunome, Inc.

NASDAQ:IMNMHealthcare
-0.44%$18.21
AH$18.88+3.66%vs close
Mkt Cap$2.15B
Float101.21M
O/S118M
Vol
$ Vol
RVOL
Inst Own100.0%
Earnings
Dilution
Immunome, Inc. logoNASDAQ:IMNM$18.21-0.44%
Upcoming Catalysts
  • varegacestatPDUFA
    progressing desmoid tumors
    Cash runway at this date: 17mo
    Apr 28, 2027in 177 daysPR
  • VaregacestatSUBMISSIONNDA ACCEPTED
    Cash runway at this date: 23mo
    Oct 30, 20263d agoPR
  • varegacestatREADOUT
    Cash runway at this date: 23mo
    Oct 26, 20267d agoPR
Phase Distribution
11 lead-sponsored trials·5 active·4 completed
Phase 110
Phase 2/31

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2/3
    Active, not recruiting

    A Study of AL102 in Patients With Progressing Desmoid Tumors

    AL102

    Desmoid, Desmoid Tumor

    Enrollment
    198
    Start
    Sep 2021
    Primary Completion
    Dec 2025READOUT • p=0.000
    Completion
    Dec 2026est.
    NCT04871282
  • Phase 1
    Terminated

    IMM-BCP-01 in Mild to Moderate COVID-19

    IMM-BCP-01, Placebo

    SARS-CoV2 Infection, COVID-19

    Enrollment
    9
    Start
    Jun 2022
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT05429021
  • Phase 1
    Completed

    A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

    varegacestat, Itraconazole (200 mg)

    Healthy Volunteer

    Enrollment
    22
    Start
    Nov 2024
    Primary Completion
    Dec 2024
    Completion
    May 2025
    NCT06677996
  • Phase 1
    Recruiting

    A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

    IM-1021

    Solid Malignancies, Hematologic Malignancies

    Enrollment
    190
    Start
    Feb 2025
    Primary Completion
    May 2028est.
    Completion
    Feb 2029est.
    NCT06823167
  • Phase 1
    Completed

    A Varegacestat Hepatic Impairment Study

    varegacestat

    Healthy Volunteer, Hepatic Impairment (HI)

    Enrollment
    35
    Start
    Mar 2025
    Primary Completion
    Nov 2025
    Completion
    Mar 2026
    NCT06841315
  • Phase 1
    Completed

    A Phase 1 Mass Balance Study of Varegacestat

    varegacestat

    Healthy Volunteer

    Enrollment
    6
    Start
    Feb 2025
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT06845852
  • Phase 1
    Completed

    A Cardiac Liability Study of Varegacestat in Healthy Participants

    varegacestat, Placebo

    Healthy Volunteer

    Enrollment
    32
    Start
    Feb 2025
    Primary Completion
    Apr 2025
    Completion
    May 2025
    NCT06855264
  • Phase 1
    Recruiting

    A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

    177Lu-IM-3050

    Solid Malignancies

    Enrollment
    105
    Start
    Jun 2026
    Primary Completion
    Dec 2029est.
    Completion
    Dec 2034est.
    NCT07505771
  • Phase 1
    Recruiting

    A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

    IM-1617

    Colorectal Cancer, Non-Small Cell Lung Cancer +4

    Enrollment
    175
    Start
    May 2026
    Primary Completion
    Jan 2029est.
    Completion
    Jan 2029est.
    NCT07578571
  • Phase 1
    Recruiting

    A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

    Varegacestat Reference Formulation, Varegacestat Test Formulation A

    Healthy

    Enrollment
    44
    Start
    May 2026
    Primary Completion
    May 2027est.
    Completion
    May 2027est.
    NCT07610005
  • Phase 1
    Not yet recruiting

    A Phase 1 Study of IM-1340 in Participants With Advanced Cancer

    IM-1340

    Colorectal Cancer, Non-Small Cell Lung Cancer +2

    Enrollment
    200
    Start
    Nov 2026est.
    Primary Completion
    Sep 2030est.
    Completion
    Sep 2030est.
    NCT07890246
Search ClinicalTrials.gov for “Immunome”